Blogs

Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update:  PTCy versus ATG for GVHD prophylaxis, cost and outcomes with once-daily busulfan dosing, carfilzomib for the treatment of chronic GVHD and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice Allogeneic Transplantation **Alatrash G, Kidwell KM, Thall PF, et al.  Reduced ...
0 comments
Be the first person to recommend this.
Please join us for the ASTCT Pharmacy SIG November Journal Club on PD-1 Blockade post HSCT and the Dosing of Conditioning Regimens in Obese Patients on Wednesday, Nov. 20, 2019 at 2:00 pm CST. Our presenters are: Gretchen Junker, PharmD , PGY2 Oncology Pharmacy Resident Kansas University PD-1 Blockade with Pembrolizumab after HSCT Joseph Bubalo, PharmD, BCPS, BCOP, Clinical Pharmacy Specialist Oregon Health and Science University Hospital and Clinics Effect of Conditioning Regimen Dose Reduction in Obese Patients This event is open to all healthcare professionals.  Please register for the event at https://attendee.gotowebinar.com/register/2697968838478151181 ...
0 comments
Be the first person to recommend this.
Since ASTCT’s founding in 1993, one of the most important aspects of the society has been connectivity. In the 25+ years since, we’ve seen the society grow and change. But one thing remains true: the society’s dedication to helping those in BMT and cellular therapy grow as individuals and institutions. ASTCT is made up of 2,200 physicians, investigators, and other health care professionals focused on the advancement of transplantation and cellular therapy. The society offers educational opportunities for everyone—from the fellow who is just beginning his or her career to the seasoned professional—and allows people from all areas of BMT and cellular therapy ...
0 comments
Be the first person to recommend this.
When Dr. John DiPersio looked around at his colleagues—people who were integral parts of the cellular therapy and BMT team, ranging from nurses and PAs to physicians—he realized something that concerned him: Not all were members of ASTCT. The former ASTCT president—and deputy director of the Siteman Cancer Center and professor in medicine in the Department of Medicine, Oncology Division at Washington University School of Medicine in St. Louis—wanted to change that. He knew that everyone could benefit from having an ASTCT membership, but also understood not everyone could afford the individual costs. “We have this entity that is dedicated to cellular therapy ...
0 comments
Be the first person to recommend this.
Mikaela VanMoorleghem, Education and Training Coordinator Foundation for the Accreditation of Cellular Therapy Data Audit Policy Update FACT-JACIE Standards for Hematopoietic Cellular Therapy require that accredited clinical programs keep complete and accurate data, including all data necessary to complete the Transplant Essential Data Forms of the CIBMTR or the Minimum Essential Data-A forms of EBMT. In August 2016, FACT and CIBMTR announced their collaborative program of data auditing, designed to reduce duplicative efforts, enhance quality improvement efforts, and provide support to accredited programs. Over the past three years, the FACT-CIBMTR ...
0 comments
Be the first person to recommend this.
Drug Pricing Legislation Drug pricing legislation has continued to progress in the 116 th Congress as the end of the year draws near. The Administration has made a strong push for drug pricing legislation to be passed in 2019. In May 2018, President Trump’s Administration laid out its Drug Pricing Blueprint , which put forth a number of different policy ideas on how to lower the cost of prescription medication. The suggestions included, drug importation, the International Pricing Index, value based purchasing and Medicare program redesign. With the end of the Congressional year quickly approaching, there is pressure from the Administration to get legislation ...
0 comments
Be the first person to recommend this.
ASTCT is calling for nominations to the Board of Directors, and there could not be a more exciting and rewarding time to get involved! The members of the ASTCT Board of Directors work diligently throughout the year to identify and implement strategy to strengthen our society and the blood and marrow transplantation and cellular therapy community. The enthusiasm, excitement, spirit of collaboration, and professional camaraderie associated with the advancement of our society is truly contagious. We have come so far—and talented and spirited leaders are needed to ensure that we continue to make progress. Serving on the Board offers a tremendous opportunity to make ...
0 comments
Be the first person to recommend this.
It didn’t matter how much training Naoto T. Ueno had, how many patients he had seen in his lifetime and how many medical books he had read. When he was sitting there on the other side of the table—as a patient and not as a doctor—nothing seemed to prepare him for how he felt. “I was scared,” said Ueno, MD, PhD, FACP. “I thought, ‘Am I going to die?’ and if I did, was it going to be slow or fast? When I was working I tried to stop worrying about it, but at home with my family, I was like ‘I can’t think about the future. I can’t visualize myself five years from now.’”   In 2008, Ueno—a world-renowned breast cancer doctor and researcher at The University of ...
0 comments
Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update: Cryotherapy as prophylaxis against oral mucositis, CD19 CAR T cells in non-Hodgkin lymphoma, risk of latent tuberculosis reactivation after HCT, fertility preservation in HCT patients and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice Allogeneic Transplantation ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, FACT Education and Training Coordinator FACT Announces Events at the 2020 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR  Cellular Therapy Inspection and Accreditation Workshop – February 18 We invite you to join us for upcoming FACT events at the 2020 TCT Meetings!  FACT will conduct a Cellular Therapy Inspection & Accreditation workshop on February 18, 2019, at the World Center Marriott in Orlando, Florida. This workshop will provide an immersive experience for personnel preparing for the accreditation process and a full day training session for FACT inspector trainees. Register for ...
0 comments
Be the first person to recommend this.
On September 27, 2019 ASTCT submitted its comments to CMS on the CY2020 Hospital Outpatient Prospective Payment System Proposed Rule. The proposed rule was released on July 29, 2019. The proposed rule follows the directives from the Presidential Executive Order (EO) entitled “Improving Price and Quality Transparency in American Healthcare to Put Patients First.” According to CMS’ press release the EO, “lay[s] the foundation for a patient-driven healthcare system by making prices for items and services provided by all hospitals in the United States more transparent for patients so that they can be more informed about what they might pay for hospital items ...
0 comments
Be the first person to recommend this.
On August 2, the Centers for Medicare & Medicaid (CMS) released the FY2020 Inpatient Prospective Payment System (IPPS) final rule that includes payment policy for chimeric antigen receptor T-cell (CAR-T) therapy. The American Society for Transplantation and Cellular Therapy (ASTCT) has been working closely with CMS to improve reimbursement for CAR-T therapy and the data the agency collects on its delivery to assure appropriate patient access to this lifesaving therapy. Despite our advocacy efforts, ASTCT is disappointed in the agency’s final payment policy as it did not significantly improve the payment policy for FY 2020 nor did it position the agency ...
0 comments
Be the first person to recommend this.
By Mikaela VanMoorleghem, FACT Education and Training Coordinator FACT-SBTMO Joint Accreditation Program Launched in Brazil Approximately 70 representatives of bone marrow transplant centers attended the FACT-SBTMO Accreditation Program Workshop on July 31, 2019; an initiative that is the result of the partnership between the Brazilian Society of Bone Marrow Transplant (SBTMO) and the Foundation for the Accreditation of Cellular Therapy.  The meeting clarified the requirements and the operational dynamics of the accreditation process for Brazilian cell therapy transplant centers. As Carlos Bachier and Phyllis Warkentin of the FACT Global Accreditation ...
0 comments
Be the first person to recommend this.
August heralds the beginning of the end for summer. Children start heading back to school. The weather begins to turn crisp. Days get shorter. Leaves start showing hints of red and yellow – very soon they will detach from the stems that have nourished them and then wither away, only to be replaced by new leaves the following spring. A patient once poignantly compared this time of the year to transplant – the end of summer was like the onset of conditioning regimen when there was less sunshine in his life, followed by the "100 days" of fall and winter – but he was hopeful he would see spring again and subsequently enjoy many summers. He considered his stem ...
0 comments
Be the first person to recommend this.
Harmonization of Busulfan Plasma Exposure Units (BPEU): A Community-Initiated Consensus Statement Attendees Jitesh D Kawedia, BSPharm, PhD, R.Ph Clinical Pharmacy Specialist The University of Texas MD Anderson Cancer Center Wednesday, September 11, 2019 1pm PST/2pm CST/3 pm EST This event is open to all healthcare professionals for members and nonmembers of ASTCT Registration. Mark your calendar and reserve your seat for this webinar here . You will receive a confirmation e-mail along with a link to access the webinar on the day of the journal club presentation We look forward to your attendance! For additional questions regarding the ASTCT Pharmacy ...
0 comments
Be the first person to recommend this.
Following the successful examples of the international symposia focusing on GVHD and relapse after HCT, this symposium will bring together experts and thought leaders from around the world in the fields of HCT, cellular therapies, and related medical subspecialties. Speakers will discuss mechanisms of toxicities and symptom burden after HCT and cellular therapies, current advances in the field, and best practices to both prevent and treat these toxicities and symptoms. When: October 11-12, 2019 Where: Memorial Sloan Kettering Cancer Center, New York, New York Register her
0 comments
Be the first person to recommend this.
In this month’s Pharmacy SIG Literature Update:  Autologous HCT in myeloma patients aged > 75 years, improved outcomes for male germ cell tumors, haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure and much more! Literature summaries are provided as information only. Please refer to the original published articles for complete details on study methodology, results and discussion. ***        Must read. Landmark publication that affects practice **           Recommend reading. Secondary paper that adds to literature *             Consider reading. Cursory importance to the practice ...
0 comments
Be the first person to recommend this.
To Dr. John Hansen, every patient was special. “Every patient that I’ve known, every patient that I’ve helped … every one of them is a precious experience,” Hansen said in an interview in 2018 . Hansen, 76, died peacefully at his home on July 31 after a battle with pancreatic cancer. Hansen left a huge mark on the bone marrow transplant community, with one of his most notable contributions being the National Marrow Donor Program, now known as Be The Match. He played an integral role in understanding how to find suitable donors for each transplant patient, establishing registries of these donors and started collections of biological samples and data that ...
0 comments
Be the first person to recommend this.
Dr. Wesley Miller was quiet at times, but when he did speak, he was worth listening to. “He was an excellent listener,” said Dr. John Bantle, one of Miller’s close friends, and a former colleague at the University of Minnesota. “He was extremely insightful and the definition of integrity. If he got into something, he didn’t do anything halfway. He did it intensively.” Miller passed away peacefully at his home on July 15 at the age of 71 after a battle with cancer. Miller was considered a pioneer at the University of Minnesota for his work in bone marrow and stem cell transplantation. He worked there for more than 40 years and was an early proponent of ...
0 comments
Be the first person to recommend this.
On Aug. 8, ASTCT President Navneet Majhail, MD, MS, submitted a letter to the Director of Coverage and Analysis Group at the Centers for Medicare and Medicaid Services Tamara Syrek Jensen, JD. In it, Majhail lauded CMS for their Decision Memo on CAR T-cell Therapy for Cancers. From Majhail's letter:  "The American Society for Transplantation and Cellular Therapy (ASTCT) is very pleased with the recent coverage announcement from The Centers for Medicare and Medicaid Services (CMS) in the Decision Memo for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG- 00451N). The Society appreciates the opportunity to work closely with the Agency on this National ...
0 comments